News

Home/News/

CEO Letter, December 2021

By |2021-12-17T10:07:27+01:00December 17th, 2021|

The year was marked by continued positive development of Dizlin’s innovative potential treatments for late stages of Parkinson´s disease and we secured financing for the upcoming steps in development. We can look back with pride over a year marked by advances in our efforts to fulfill our ambition: to improve the quality of life for Parkinson patients with late-stage complications, such as shifts in motor function from immobility to involuntary movements.

It is satisfying to announce that we during the last quarter successfully managed to secure financing that enables us to continue our journey to create value for patients, shareholders, and society at large. Dizlin Pharmaceuticals has two potential products containing levodopa-carbidopa solutions in late development stage. The first, Infudopa SubC™, is a treatment for reducing motor complications of Parkinson’s disease via continuous subcutaneous infusion administered by a portable pump (similar to insulin infusion for diabetes). The second, Infudopa IntraV™, is administered intravenously to minimize risks associated with surgery on patients with Parkinson’s disease.

Another important milestone was finalizing the partnership for the upcoming commercial production of the portable pump, which is required for the administration of Infudopa SubC™. A clinical study has shown that our product can yield high and even levels of levodopa which is a prerequisite for being able to provide Infudopa SubC™ as a monotherapy. Infudopa SubC™ can be expected to provide at least the same efficacy as the most effective treatment available for advanced Parkinson’s disease, but without the need to implant a tube into the intestine. We have kicked off the collaboration with a manufacturer with extensive experience of producing pumps in line with our expectations and requirements.

In addition, we recently chose a partner for process development activities and for production of clinical trial material. Our efforts and investment in relation to chemistry, manufacturing, and controls (CMC) are critical for the ongoing projects. This is to ensure that we have clinical trial material for pivotal studies and ultimately a commercially viable production process in place.

Regarding our second product, Infudopa IntraV™, our goal is to commence a final minor clinical bioequivalence and tolerability study mid-2022. This product is intended for intravenous treatment to both enable and facilitate surgical procedures for Parkinson patients. During the year, we have initiated follow-up interactions with the health authorities in Europe and the US with the aim to file our applications for market authorization with both the EMA and FDA after completion of the final study.

Strong patents are critical to protect scientific advances. Therefore, an active patent strategy is a precondition for maximizing the commercial value of Dizlin’s scientific advances. In the beginning of the year, we were pleased to obtain a “Decision to Grant” by the European Patent Office regarding Infudopa SubC™.

Two years have passed since I joined the company as CEO, and I am proud of what the team has accomplished so far. We will now continue our important efforts to develop treatments that can improve the quality of life for Parkinson patients and their families. Thank you all for your interest in Dizlin Pharmaceuticals and I wish you all the best for the Holiday Season and the New Year.

Björn Velin
CEO, Dizlin Pharmaceuticals AB

Dizlin Pharmaceuticals AB appoints Daniel Mackey as Chief Financial Officer

By |2021-11-02T13:49:44+01:00November 1st, 2021|

Dizlin Pharmaceuticals announces the appointment of Daniel Mackey as Chief Financial Officer (CFO) effective as of November 1, 2021.

Daniel Mackey brings to Dizlin Pharmaceuticals more than 20 years of finance and controlling experience. Prior to joining the company, Daniel has a background in the finance and life science sector. He has held senior management positions at Nordea in Stockholm, Investors Trust Ireland in Dublin, and most recently the CFO position at Infant Bacterial Therapeutics AB, a pharmaceutical company listed on Nasdaq Stockholm. He holds a BS, Economics from State University of New York College at Plattsburgh, in the US.

“I am pleased to announce that Daniel Mackey has joined our Executive Management Team as CFO. Daniel’s competence, extensive experience in finance and controlling as well as his strategic knowledge will play an important role for Dizlin Pharmaceuticals moving forward. We are excited to have him on board,” says Björn Velin, CEO of Dizlin Pharmaceuticals.

“I look forward to contribute and advance Dizlin Pharmaceuticals’ financial and business objectives that will support and further strengthen the company’s position as a pharmaceutical research company developing new innovative treatments for late stages of Parkinson´s disease,” added Daniel Mackey, Dizlin Pharmaceuticals’ Chief Financial Officer.

Michael Owens, who previously held the position as CFO will continue as Controller, thus ensuring a smooth transition, as well as supporting the company regarding external financial reporting matters.

For more information, please contact:

Björn Velin, CEO of Dizlin Pharmaceuticals AB, + 46 (0)76 879 2325, bjorn.velin@dizlin.se

Dizlin Pharmaceuticals has obtained a “Decision to Grant” by the European Patent Office for Infudopa SubC™, a new potential treatment for Parkinson’s disease

By |2021-11-02T13:48:03+01:00February 4th, 2021|

Dizlin Pharmaceuticals announced today that the European Patent Office (EPO) has issued a Decision to Grant a European patent pursuant to Article 97(1) EPC following examination of European patent application No. 18730319.3. The mention of the Grant was published in the European Patent Bulletin 21/04 on the 27th of January 2021. The Decision to Grant refers to Infudopa SubC™, a new potential treatment for reducing motor complications of Parkinson’s disease via continuous subcutaneous infusion.

A granted patent by EPO will protect the company’s innovative product Infudopa SubC™ for treatment of Parkinson’s disease in all markets in Europe, which have agreed to the Patent Cooperation Treaty (PCT) agreement.

”Strong patents are a prerequisite for successfully commercializing Dizlin Pharmaceutical’s scientific advances. I am therefore pleased to announce that the European Patent Office has decided to issue a Decision to Grant for the company’s innovative product Infudopa SubC™ for the treatment of Parkinson’s disease. This is an important milestone, not only pursuing the company’s patent strategy, but also in our aim to improve the lives of the Parkinson patients,” says Björn Velin, CEO of Dizlin Pharmaceuticals.

For more information, please contact:
Björn Velin, CEO of Dizlin Pharmaceuticals AB, + 46 (0)76 879 2325, bjorn.velin@dizlin.se

Positive final results from pharmacokinetic study (PK) with Infudopa SubC™ and Infudopa IntraV™ (IPO-001)

By |2020-11-25T15:14:50+01:00November 24th, 2020|

In a pharmacokinetic cross-over study, 18 patients with Parkinson´s disease were assessed for 16 hours with respect to blood levels of levodopa when administered levodopa plus carbidopa subcutaneously (Infudopa SubC™), intravenously (Infudopa IntraV™) or intestinally (Duodopa®/Duopa®).

The primary aims of the study, to show bioequivalence of Infudopa SubC™ and Duodopa®/Duopa® with respect to levodopa levels in plasma, and non-inferiority with respect to plasma level fluctuations, were all met. A comparison of levodopa levels following Infudopa SubC™ and Infudopa IntraV™, respectively, shows levodopa bioavailability for Infudopa SubC™ to be close to 100%. Effects on motor symptoms were the same for the three treatment groups. Local side effects of Infudopa SubC™ at the infusion site were mild or moderate.

“We are very much encouraged by these results that show that all the primary aims of the study were met,” says Björn Velin, CEO of Dizlin Pharmaceuticals. “The rapid increase in levodopa levels following subcutaneous administration, and the high concentrations obtained, indicate that Infudopa SubC™ may serve as a flexible monotherapy also for patients requiring high levodopa doses.”

For more information, please contact:
Björn Velin, CEO, Dizlin Pharmaceuticals AB
Mobile: + 46 (0)76 879 23 25
E-mail: bjorn.velin@dizlin.se

Report from the General Meeting of Dizlin Pharmaceuticals AB

By |2020-10-06T11:53:31+02:00May 28th, 2020|

Dizlin Pharmaceuticals held a General Meeting on May 28, 2020.

The ordinary board members Leif Bring, Staffan Schüberg, Elias Eriksson, Anders Stenström and Nil Dizdar were re-elected. Anders Tullgren, Åsa Hansdotter and Johan von Heijne were elected as new board members. Leif Bring was re-elected as Chairman of the Board. All were elected for a term of office extending until the end of the next Annual General Meeting.

Clinical update

By |2020-11-24T17:03:55+01:00March 31st, 2020|

Researchers at Sahlgrenska Academy, in Gothenburg, Sweden, have finalized the clinical pharmacokinetic trial where Infudopa SubC™ and Infudopa IntraV™ have been compared with Duodopa®/Duopa® with respect to serum levodopa levels in 18 patients with late stage Parkinson´s disease. Dizlin Pharmaceuticals expect analyzed data in H2 2020.

Dizlin Pharmaceuticals appoints Chief Commercial Officer

By |2020-07-31T16:17:58+02:00October 20th, 2019|

Henrik Martinsson has been appointed CCO of Dizlin Pharmaceuticals and he joined the company on October 1st.

Henrik Martinsson has worked 20 years in the medical device business, mostly for Abbott in different roles. Most recently, he was the CEO for a Swedish distributor company selling medical device equipment within Ophthalmology to hospitals, private clinics and opticians.

“We are happy to bring Henrik Martinsson onboard our team. He will bring an extensive additional knowledge to Dizlin Pharmaceuticals with respect to business development and in the area of medical devices,” says Björn Velin, CEO of Dizlin Pharmaceuticals AB.

Dizlin Pharmaceuticals strengthens the collaboration with the Sahlgrenska Academy in Gothenburg

By |2020-07-31T16:18:17+02:00October 10th, 2019|

In order to further strengthen Dizlin Pharmaceuticals’ collaboration with researchers at the Sahlgrenska Academy at the University of Gothenburg, the company has agreed to sponsor a PhD position at the Department of Pharmacology.

The research collaboration is focused on Parkinson’s disease with the aim to get new insights in the understanding of the brain disorder. This can be of great value for Dizlin Pharmaceuticals in the company’s ambition to develop innovative and effective products that improve the quality of life for Parkinson patients.

Dizlin Pharmaceuticals moves its headquarters to Gothenburg

By |2020-07-31T16:18:33+02:00September 2nd, 2019|

The headquarters of Dizlin Pharmaceuticals was relocated to Gothenburg as of September 1st.

“The relocation of our headquarters to Gothenburg enables us to be closer to the Sahlgrenska Academy and the Sahlgrenska University Hospital in Gothenburg where most of our research is being undertaken,“ says Björn Velin, CEO of Dizlin Pharmaceuticals AB.

The company’s headquarters was previously located in Uppsala

Dizlin Pharmaceuticals recruits a new CEO

By |2020-08-03T11:02:08+02:00September 1st, 2019|

Dizlin Pharmaceuticals has appointed Björn Velin as CEO and he joined the company as of September 1st. Björn Velin has a long and solid experience from the pharmaceutical industry and especially from leading positions in the areas of sales and development of medical drugs for treatment of diseases in the central nervous system.

Björn Velin has worked for more than 25 years at Lundbeck in various roles and most recently as President of Lundbeck in Japan.

“We are pleased to announce the recruitment of Björn Velin as CEO of Dizlin Pharmaceuticals. This appointment marks an important step for the development of our business and the future of the company,” comments Leif Bring, Chairman of the Board.

Go to Top